Denosumab, a monoclonal antibody targeting receptor activator of nuclear factor-kappa B ligand (RANKL), has demonstrated efficacy in giant cell tumors of bone and has been increasingly explored as a treatment option for aneurysmal bone cysts (ABCs) and osteoblastomas. Here, TNFSF11 is linked to bone giant cell tumor.